Tuesday, June 17, 2008

Study: 53% of Pharma Patents Approach Expiration Before Litigation Strategies are Implemented

A new study developed by market intelligence firm Cutting Edge Information reveals that the majority of pharmaceutical companies are waiting until their patents on drugs are nearly run out before they start to work on patent litigation strategies.

According to the study:

• 66% do not begin counter-generics planning until at least two years after product launch.

• Some companies do consider generics problems relatively early – 23% of surveyed companies conduct generics planning while drugs are still in clinical trials, and another 11% initiate counter generics strategy during launch.

• A majority of responding companies report first considering generics within four years of patent expiration (33% of companies reported to looking into litigation as a strategy while two to four years remain on the patent. Another 13% of companies began looking into litigation to protect their drugs while four to six years remained on the patent).

Download a summary of the 153-page report here (free registration required).

Purchase a copy of the report ($7695.00) here.

Seja o primeiro a comentar

DISCLAIMER

This Blog/Web Site ("Blog") is for educational purposes only and is not legal advice. Use of the Blog does not create any attorney-client relationship between you and Peter Zura or his firm. Persons requiring legal advice should contact a licensed attorney in your state. Any comment posted on the Blog can be read by any Blog visitor; do not post confidential or sensitive information. Any links from another site to the Blog are beyond the control of Peter Zura and does not convey his, or his past or present employer(s) approval, support, endorsement or any relationship to any site or organization.

The 271 Patent Blog © 2008. Template by Dicas Blogger.

TOPO